Yuka Saito

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.

Summary of studies on space solar power systems of Japan Aerospace Exploration Agency (JAXA)

Hideshi Kagawa, Yuka Saito, Masahiro Mori, 2006 .